Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Merck
Baxter
Express Scripts
Harvard Business School

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,272,144

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,272,144
Title:Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
Abstract: Compositions useful to induce anti-TACA immune response and kits comprising the same and methods of using the compositions to treat and prevent cancer are disclosed. Isolated human antibodies which bind to a carbohydrate mimetic peptide and methods of making the same and using the same to treat and prevent cancer are disclosed. Isolated human NK cells useful to kill tumor cells, and isolated human dendritic cells, and methods of making the same and using the same to treat and prevent cancer are disclosed.
Inventor(s): Kieber-Emmons; Thomas (Little Rock, AR), Pashov; Anastas (Little Rock, AR), Karbassi; Behjatolah (Little Rock, AR)
Assignee: BioVentures, LLC (Little Rock, AR)
Application Number:14/908,503
Patent Claims:1. A method of treating a human who has been diagnosed as having breast cancer, wherein the breast cancer is selected from the group consisting of i) triple negative breast cancer and ii) breast cancer that is HER2 positive, the method comprising administering to said human a composition comprising a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Leu-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is cyclohexylalanine, a modified L configuration Alanine shown as CHAla.

2. The method of claim 1 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy.

3. The method of claim 1 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

4. The method of claim 1, wherein a) the composition further comprises an anti-cancer chemotherapeutic or anti-cancer radioactive agent, or b) the composition is a component in a kit comprising a first container that comprises the composition and a second container comprising an anti-cancer chemotherapeutic or anti-cancer radioactive agent.

5. The method of claim 1 wherein the composition further comprises an adjuvant.

6. The method of claim 5 wherein the adjuvant is selected from the group consisting of an oil and surfactant adjuvant and QS21 adjuvant.

7. The method of claim 5 wherein the adjuvant is an oil and surfactant adjuvant, wherein the oil is mineral oil and the surfactant is mannide monooleate.

8. The method of claim 1 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g.

9. The method of claim 1 wherein the human is further treated with surgery and/or chemotherapy.

10. The method of treating a human who has been diagnosed as having triple negative breast cancer, the method comprising administering to said human a composition comprising a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Leu-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is cyclohexylalanine, a modified L configuration Alanine shown as CHAla.

11. The method of claim 10 wherein the human is also treated with surgery and/or chemotherapy.

12. The method of claim 10 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

13. The method of claim 1 wherein the human is identified as having a tumor that is HER2 positive.

14. The method of claim 13 further comprising treating the human with chemotherapy.

15. The method of claim 14 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

16. The method of claim 7 wherein the human is further treated with surgery and/or chemotherapy.

17. The method of claim 7 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

18. A method of treating a human who has been diagnosed as having triple negative breast cancer, the method comprising administering to said human a composition comprising: a compound having the structure of Formula 1: Trp-Arg-Tyr-Thr-Ala-Pro-Val-His-Leu-Gly-Asp-Gly-dAla-Lys-CHAla-Val-Ala-Al- a-Trp-Thr-Len-Lys-Ala-Ala-dAla-NH.sub.2 Formula 1 wherein Ala13 and Ala25 are each D amino acids shown as dALa, and Ala at position 15 is Cyclohexylalanine, a modified L configuration Alanine shown as CHAla, and an oil and surfactant adjuvant, wherein the oil is mineral oil and the surfactant is mannide monooleate.

19. The method of claim 18 wherein the human is also treated with surgery and/or chemotherapy.

20. The method of claim 18 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

21. The method of claim 7 wherein the human is identified as having a tumor that is HER2 positive.

22. The method of claim 21 further comprising treating the human with chemotherapy.

23. The method of claim 22 further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: doxorubicin, cyclophosphamide, docetaxel, cisplatin, vinorelbine, bortezomib, adriamycin, trastuzumab, paclitaxel, tamoxifen and pertuzumab.

24. The method of claim 10 wherein the human who has been diagnosed as having triple negative breast cancer has been diagnosed as having metastatic triple negative breast cancer.

25. The method of claim 18 wherein the human who has been diagnosed as having triple negative breast cancer has been diagnosed as having metastatic triple negative breast cancer.

26. The method of claim 11 wherein the human is also treated with chemotherapy and surgery.

27. The method of claim 11 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel.

28. The method of claim 27 wherein the human is also treated with surgery.

29. The method of claim 13 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel.

30. The method of claim 13 wherein said breast cancer that is HER2 positive is metastatic.

31. The method of claim 19 wherein the human is also treated with chemotherapy and surgery.

32. The method of claim 19 comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel.

33. The method of claim 32 wherein the human is also treated with surgery.

34. The method of claim 21, further comprising treating the human with one or more anti-cancer chemotherapeutics selected from the group consisting of: docetaxel and paclitaxel.

35. The method of claim 21 wherein said breast cancer that is HER2 positive is metastatic.

36. The method of claim 10 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy.

37. The method of claim 10 wherein composition further comprises adjuvant.

38. The method of claim 37 wherein adjuvant is selected from the group consisting of an oil and surfactant adjuvant and QS21 adjuvant.

39. The method of claim 10 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g.

40. The method of claim 18 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy.

41. The method of claim 18 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g.

42. The method of claim 7 further comprising treating the human with one or more anti-cancer chemotherapeutics, anti-cancer radioactive agent and/or with anti-cancer radiation therapy.

43. The method of claim 7 wherein the composition comprises the compound having the structure of Formula 1 in an amount selected from the group consisting of: at least 300 .mu.g, at least 500 .mu.g, and at least 1000 .mu.g.

Details for Patent 10,272,144

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Sign up for a Free Trial 2033-07-31
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Sign up for a Free Trial 2033-07-31
Genentech, Inc. PERJETA pertuzumab Injection 125409 2012-06-08 ⤷  Sign up for a Free Trial 2033-07-31
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 2019-02-28 ⤷  Sign up for a Free Trial 2033-07-31
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Merck
Dow
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.